1-2 of 2
Mathieu Chiquet, BSc
Close
Sort by
Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5497.
https://doi.org/10.1182/blood-2018-99-114212
Published: 2018
Journal Articles

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Rose Ann Padua, PhD, Mathieu Chiquet, BSc, Qi Zhang, PhD MD, Claire Kappel, Patricia Krief, PhD, Niclas Setterblad, PhD, Dr Omidvar, BSc, MSc, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2613.
https://doi.org/10.1182/blood.V130.Suppl_1.2613.2613
Published: 2017